Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SLNO | Common Stock | Award | $0 | +850K | +636.54% | $0.00 | 984K | Jul 17, 2024 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. 25% of the RSUs subject to the award shall vest on August 1, 2024, 25% of the RSUs subject to the award shall vest on the date that the U.S. Food and Drug Administration (FDA) accepts the Company's New Drug Application (NDA) for DCCR, and 50% of the RSUs subject to the award shall vest on the date that the FDA approves the Company's NDA for DCCR (the NDA Approval Date), subject to the Reporting Person continuing as a service provider through each such date. |
F2 | Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |